Details of the 2014 BioTrinity Programme will be announced shortly

 

BioTrinity 2013: Panel Discussions and Key Notes - 14-16 May, 2013


View the Gallery of Panel Discussions and Workshops at BioTrinity 2011

A number of excellent plenary sessions and panel discussions from key opinion leaders are scheduled for BioTrinity 2014, running during the mornings of the 13th and 14th of May, featuring senior licensing professionals from global pharma. Last year’s panel discussions featured AbbVie, AstraZeneca, GSK, Ipsen, MSD, Shire, BMS, Amgen, Takeda, Astellas, Eli Lilly and Company as well corporate and strategic venturer and VC's such as Syncona Fund, SR One, Novartis Venture Fund, MedImmune Ventures, Index Ventures, NeoMed, Forbion, Sofinnova Partners, EdRIP, Boehringer-Ingelheim GMbH and Novo A/S.

BioTrinity 2013 also featured the UK presentation of Ernst & Young’s Beyond Borders 2013. 

The Panel Sessions ran along the following themes:

  • "Corporate VC 2013: Now Part of the Furniture?"
  • "Exit Structures: Are Pharma and VC Aligned?"
  • "The Ten Year LP Fund: An Endangered Species?"
  • "Incubators, Science Parks, Seed-stage and Spin-outs: How They Form and How to Get in There"
  • "Innovative Financing & Deferred Consideration: Essential Parts of Deal Terms?"
  • "Europe: The Bioincubator of the World?"
  • "The Seasoned Hands at Venture Investment: Is This Crisis Different?"
  • "War Games: An interactive session where investors, board members and CEOs respond to challenging events that occur in the life of a fictional biotech company"
  • What will the European fundraising landscape hold for life sciences in 2013/14 – The view from the markets

Day One - Wednesday 15 May 2013

09:00-09:10 Welcome and Opening Remarks:
Jon Rees, CEO, OBN (UK)
09:10-09:20 VIP Address:
To be announced - Subscribe to "Keep me Informed" to be the first to know

09:25-10:10 Corporate VC 2013: Now Part of the Furniture?
Hamish Cameron, Venture Partner, SV Life Sciences - Chair (UK)
Margarita Chavez, Director, Venture Investments, AbbVie (USA)
Graeme Martin, President and CEO, Takeda Ventures, Inc. (USA)
Matt Foy, Partner, SR One (UK)
Ilke Wicke, Director: Investment Manager of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim Venture Fund GMbH (Germany)

10:10-10:50 Exit Structures: Are Pharma and VC Aligned?
 
Lisa Urquhart, Editor, EP Vantage - Chair (UK)
Olivier Litzka, Partner, Edmond de Rothschild Investment Partners (France)
Christina Takke, Partner, Forbion Capital Partners (Netherlands)
Lubor Gaal, Head of Europe, Strategic Transactions Group, Bristol-Myers Squibb (UK)
Martin Edwards, Chairman, Novo A/S (Denmark)
Denise Goode, Executive Director, AstraZeneca (UK)

10:50-11:10 Refreshments, Networking, Exhibition

11:10-11:50 The Seasoned Hands at Venture Investment: Is This Crisis Different?
Olivier Litzka, Partner, Edmond de Rothschild Investment Partners - Chair (France)
Deborah Harland, Partner, SR One (UK)
Gwen Melincoff, SVP, Business Development and Strategic Investing, Shire (USA)
Tim Haines, Partner, Abingworth (UK)
Holger Reithinger, General Partner, Forbion Capital Partners (Germany)

11:50-12:20 The Ten Year LP Fund: An Endangered Species?
Martin Murphy, CEO, Syncona Partners LLP - Chair (UK)
Mike Gutch, Managing Director, Medimmune Ventures (USA)
Kevin Johnson, Partner, Index Ventures (UK)
Graziano Seghezzi, Partner, Sofinnova Partners (France)
Dina Chaya, Venture Partner, NeoMed (Switzerland)
Anja Koenig, Managing Director, Novartis Venture Fund (Switzerland)

17:00-17:30 What will the European fundraising landscape hold for life sciences in 2013/14 – The view from the markets
Shawn Manning, MD, Akesios Associates - Chair (UK)
James Steel, Head of Corporate Life Sciences, Peel Hunt LLP (UK)
Juliet Thompson, Managing Director, Nomura Code (UK)
Geraldine O’Keeffe, Fund Manager, Life Science Partners (Netherlands)
Nigel Barnes, Partner, WG Partners LLP (UK)

Day Two - Thursday 16 May 2013

09:00-09:25 Keynote: Returning 3x to Investors
  Bryan Morton, Founder (Former CEO), EUSA Pharma

09:25-10:10 Innovative Financing and Deferred Consideration: Essential Parts of Deal Terms?
John Carroll, Editor, Fierce Biotech - Chair (USA)
Tim Herpin, VP SPBD, Oncology and STL, AstraZeneca (UK)
David Colpman, Global Head of Business Development, Shire (UK)
Patrick Verheyen, Head of Innovation, London and VP New Ventures, Johnson & Johnson(UK)
Stewart Kay, Director, Transactions, GlaxoSmithKline (UK)
Scott Cuthill, Director, Corporate Business Development, Ipsen Biopharm Ltd

10:10-10:50 Europe: The Bioincubator of the World?
Rob Pinnock, Regional Licensing and Acquisitions Lead, MSD - Chair (UK)
Mike Gutch, Managing Director, Medimmune Ventures (USA)
Alan Lamont, Executive Managing Director, Eli Lilly and Company (UK)
Ian Moules, Senior Director, Takeda Pharmaceuticals (UK)
Sven Rohmann, MD, General Manager Europe, Venture Partner & Managing Director Digital Health, Burrill & Company (Switzerland)

10:50-11:10 Refreshments, Networking, Exhibition

11:10-11:50 Incubators, Science Parks, Seed-stage and Spin-outs: How They Form and How to Get in There
Glenn Crocker, Chief Executive Officer, BioCity - Chair (UK)
James Dipple, Managing Director, MEPC (UK)
Martino Picardo, Chief Executive Officer, Stevenage Bioscience Catalyst (UK)
Sally-Ann Forsyth, Director, Goodman (UK)
David Phillips, Partner, SR One (UK)
Graham Hewson, Incubator Centre Manager, Imperial Innovations (UK)

11:50-12:20 War Games:
David Yeary, Vice President Sales Life Sciences, Merrill Datasite - Chair (UK)
Malcolm Young, CEO, e-Therapeutics plc (UK)
Tacye Connolly, Director, Regulatory Resources Group (UK)
Sofia Ioannidou, Associate, Edmond de Rothschild Investment Partners (France)
Maciek Drozdz, Investment Manager, Entrepreneurs Fund (UK)
                                              





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
86 global pharma/medtech delegates
33 corporate venture delegates